

MARKET REPORT



Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast-2023

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast-2023

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast-2023

Acne vulgaris is a common chronic skin disease/Disorder of pilosebaceous follicles. The disease is characterized by blockage and/or inflammation of hair follicles and their accompanying sebaceous gland. Acne develops in regions of high sebaceous gland. The disease is seen to occur mostly in adolescence. At puberty androgens due to the increase in sebum production from enlarged sebaceous glands, the glands become blocked. Propionibacterium acnes further colonise and lead to lesion production although its exact role is unclear.

DelveInsight's "Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast-2023" Report provides an overview of the disease and market size of the Acne Vulgaris for the global, United States, EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan for 2013-2023. It also includes global historical and forecasted epidemiological data for the Acne Vulgaris Diagnosed Cases from 2013-2023. According to DelveInsight, the Diagnosed cases in 7 major markets for Acne Vulgaris (AV) were 113,959,366 cases in 2013 and are expected to be 136,929,289 cases in 2023.

As per DelveInsight's estimation, the global market size of Acne Vulgaris (AV) was USD 5,360.1 Millions in 2013 and is expected to reach USD 14,226.3 Million by the end of 2023.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Scope

- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- Marketed information including available prescription drugs.
- The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.
- It also provides Market size of Acne Vulgaris (AV) for United States, EU5 and Japan from 2013 and forecasted Market size to 2023.

Acne Vulgaris (AV) Market (7MM)

Acne Vulgaris (AV) Market forecasting

Acne Vulgaris (AV) Sales forecasting

Acne Vulgaris (AV) Market segments

Acne Vulgaris (AV) Epidemiology

Acne Vulgaris (AV) Pipeline products and technologies

Acne Vulgaris (AV) Competitive landscape

Acne Vulgaris (AV) SWOT analysis

Acne Vulgaris (AV) Market Driver's and barriers

Acne Vulgaris (AV) Key Companies and Funding

Additional Details

Publisher : Delve Insight

Reference : DIMI0008

Number of Pages : 88

Report Format : PDF

Publisher Information :



The image shows a person in a white lab coat holding a report cover. The report cover features the DelveInsight logo at the top, a cityscape with red construction cranes, and the text 'BioPortfolio Life Science Healthcare and Pharmaceutical Global Market Research and Corporate Data'. In the background, there is a laboratory setting with a hand in a blue glove holding a pipette over a multi-well plate. To the right of the report, the text 'BioPortfolio Life Science Healthcare and Pharmaceutical Market Research and Corporate Data' is displayed in blue. Below this, 'Best Prices Guaranteed' is written in red, and 'bioportfolio.co.uk' is written in blue at the bottom.

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Table Of Contents for Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast-2023 [Report Updated: 01-03-2017]

- Report IntroductionAcne Vulgaris Market Overview at a GlanceTotal Market Size of Acne Vulgaris for 7 MM in 2010-2023Total Market Share Distribution of Acne Vulgaris for 7 MM in 2015Total Market Share Distribution of Acne Vulgaris for 7 MM in 2023Acne VulgarisOverviewSigns and symptomsTypes of AcnePathophysiologyDiagnosisEpidemiology and Patient PopulationUnited StatesDiagnosed Cases of Acne Vulgaris in United StatesGermanyDiagnosed Cases of Acne Vulgaris in GermanyFranceDiagnosed Cases of Acne Vulgaris in FranceUnited KingdomDiagnosed Cases of Acne Vulgaris in United KingdomSpainDiagnosed Cases of Acne Vulgaris in SpainItalyDiagnosed Cases of Acne Vulgaris in ItalyJapanDiagnosed Cases of Acne Vulgaris in JapanTreatment AlgorithmMarketed DrugsTop Marketed Drugs for Acne VulgarisAcanya: Valeant PharmaceuticalsDrug DescriptionMechanism of ActionRegulatory MilestonesAdvantages & DisadvantagesSafety and Efficacy of AcanyaProduct ProfileTazorac: AllerganDrug DescriptionMechanism of ActionRegulatory MilestonesAdvantages & DisadvantagesSafety and Efficacy of TazoracProduct ProfileVeltin: Almirall, S.A.Drug DescriptionMechanism of ActionRegulatory MilestonesAdvantages & DisadvantagesProduct ProfileDuac: GlaxosmithklineDrug DescriptionMechanism of ActionRegulatory MilestonesAdvantages & DisadvantagesProduct ProfileEpiduo and Epiduo Forte: Galderma S.A.Drug DescriptionMechanism of ActionRegulatory MilestonesAdvantages & DisadvantagesSafety and Efficacy of EpiduoProduct ProfileEmerging TherapiesMajor Pipeline drugsSarecycline: Paratek PharmaceuticalsRegulatory MilestonesAdvantages & DisadvantagesProduct ProfileClinical DevelopmentClinical Pipeline ActivityOngoing Trials InformationClinical Trial by PhaseAczone reform: AllerganAdvantages & DisadvantagesProduct ProfileSB204: Novan, Inc.Advantages & DisadvantagesProduct ProfileClinical DevelopmentClinical Pipeline ActivityOngoing Trials InformationClinical Trial by PhaseGlobal Acne Vulgaris: Country-Wise Market AnalysisOverview on Total Acne Vulgaris Market (2015)Overview on Total Acne Vulgaris Market (2023)United States Market SizeEurope Market SizeUnited Kingdom Market SizeGermany Market SizeFrance Market SizeItaly Market SizeSpain Market SizeJapan Market SizeMarket DriversMarket RestraintsAppendixReport MethodologyConsulting ServicesDisclaimerAbout DelveInsight

List Of Tables in Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast-2023 [Report Updated: 01-03-2017]

Table 1: Diagnosed Cases Acne Vulgaris in United States (2013-2023)

Table 2: Diagnosed Cases Acne Vulgaris in Germany (2013-2023)

Table 3: Diagnosed Cases Acne Vulgaris in France (2013-2023)

Table 4: Diagnosed Cases Acne Vulgaris in United Kingdom (2013-2023)

Table 5: Diagnosed Cases Acne Vulgaris in Spain (2013-2023)

Table 6: Diagnosed Cases Acne Vulgaris in Italy (2013-2023)

Table 7: Diagnosed Cases Acne Vulgaris in Japan (2013-2023)

Table 8: List of Marketed Drugs for Acne Vulgaris

Table 9: List of Pipeline Phase III Drugs for Acne Vulgaris

Table 10: Sarecycline, Clinical Trials by Zone, 2016

Table 11: Clinical Trials by Trial status, 2016

Table 12: SB204, Clinical Trials by Zone, 2016

Table 13: Clinical Trials by Trial status, 2016

Table 14: United States Market Size of Acne Vulgaris in USD, Million (2013-2023)

Table 15: United Kingdom Market Size of Acne Vulgaris in USD, Million (2013-2023)

Table 16: Germany Market Size of Acne Vulgaris in USD, Million (2013-2023)

Table 17: France Market Size of Acne Vulgaris in USD, Million (2013-2023)

Table 18: Italy Market Size of Acne Vulgaris in USD, Million (2013-2023)

Table 19: Spain Market Size of Acne Vulgaris in USD, Million (2013-2023)

Table 20: Japan Market Size of Acne Vulgaris in USD, Million (2013-2023)

List Of Figures, Charts and Diagrams in Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast-2023 [Report Updated: 01-03-2017]

Figure 1: Cellular mechanisms hypothesized to govern the pathogenesis of Acne Vulgaris

Figure 2: Diagnosed Cases of Acne Vulgaris in United States (2013-2023)

Figure 3: Diagnosed Cases of Acne Vulgaris in Germany (2013-2023)

Figure 4: Diagnosed Cases of Acne Vulgaris in France (2013-2023)

Figure 5: Diagnosed Cases of Acne Vulgaris in United Kingdom (2013-2023)

Figure 6: Diagnosed Cases of Acne Vulgaris in Spain (2013-2023)

Figure 7: Diagnosed Cases of Acne Vulgaris in Italy (2013-2023)

Figure 8: Diagnosed Cases of Acne Vulgaris in Japan (2013-2023)

Figure 9: Sarecycline, Clinical Trials by Zone (%), 2016

Figure 10: Sarecycline, Clinical Trials by Trial status (%), 2016

Figure 11: SB204, Clinical Trials by Zone (%), 2016

Figure 12: SB204, Clinical Trials by Trial status (%), 2016

Figure 13: Total Market Size of Acne Vulgaris in USD, Million (2015)

Figure 14: Total Market Size of Acne Vulgaris in USD, Million (2023)

Figure 15: United States Market Size of Acne Vulgaris in USD, Million (2013-2023)

Figure 16: United Kingdom Market Size of Acne Vulgaris in USD, Million (2013-2023)

Figure 17: Germany Market Size of Acne Vulgaris in USD, Million (2013-2023)

Figure 18: France Market Size of Acne Vulgaris in USD, Million (2013-2023)

Figure 19: Italy Market Size of Acne Vulgaris in USD, Million (2013-2023)

Figure 20: Spain Market Size of Acne Vulgaris in USD, Million (2013-2023)

Figure 21: Japan Market Size of Acne Vulgaris in USD, Million (2013-2023)

How to Buy...

Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast-2023 [Report Updated: 01-03-2017]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/105345>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$4950** | Single User Price
- \$9900** | Site License Price
- \$14850** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.